Home › Companies › REVOLUTION MEDICINES INC. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and REVOLUTION MEDICINES INC.’s Form 8-K, filed June 27, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 26, 2025: 6 items on REVOLUTION MEDICINES INC.’s Form 8-K, filed June 27, 2025: 2 approved · 4 passed (calculated).
Notable dissent: 3 directors (19.1%, 14.5%, 14.5% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore REVOLUTION MEDICINES INC. in the interactive database Compare manager voting policies
These tallies are REVOLUTION MEDICINES INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 27, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Frank K. Clyburn, Jr. | 147,380,169 | -- | -- | 512,898 | 10,241,664 | 99.7% | Passed (calculated) | — |
| Elect Director: Sandra J. Horning, M.D. | 126,395,644 | -- | -- | 21,497,423 | 10,241,664 | 85% | Passed (calculated) | — |
| Elect Director: Sushil Patel, Ph.D. | 126,396,068 | -- | -- | 21,496,999 | 10,241,664 | 85% | Passed (calculated) | — |
| Elect Director: Thilo Schroeder, Ph.D. | 119,696,091 | -- | -- | 28,196,976 | 10,241,664 | 81% | Passed (calculated) | — |
| 2. The appointment, by the audit committee of the Company's board of directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025 | 157,875,830 | 214,963 | 43,938 | -- | -- | 99.9% | Approved | — |
| 3. On a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC | 145,265,825 | 2,597,920 | 29,322 | -- | 10,241,664 | 98% | Approved | — |
Source: REVOLUTION MEDICINES INC., Form 8-K, filed with the SEC on June 27, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
285 asset managers disclosed a vote on at least one REVOLUTION MEDICINES INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 6 wordings of this item as funds reported it.
99.7% Majority: yes · of votes cast
Description as filed by funds: To elect four Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until his or her successor is elected: Frank K. Clyburn, Jr.
REVOLUTION MEDICINES INC.’s own tally for this item (“Elect Director: Frank K. Clyburn, Jr.”): 147,380,169 for, 512,898 withheld, per its Form 8-K filed June 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99.7% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 84 asset managers below reported 61,984,533 for, 15,382 withheld, 0 abstained, 87 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 22,155,786 | 0 | 0 | 0 | For |
| Fidelity | 9,184,298 | 0 | 0 | 0 | For |
| T. Rowe Price | 5,370,441 | 0 | 0 | 0 | For |
| BlackRock | 5,206,044 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 4,687,672 | 0 | 0 | 0 | For |
| JPMorgan | 2,073,815 | 0 | 0 | 0 | For |
| State Street | 1,992,023 | 0 | 0 | 0 | For |
| Charles Schwab | 1,964,933 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 956,381 | 0 | 0 | 0 | For |
| Equitable | 632,050 | 0 | 0 | 0 | For |
| American Century | 612,358 | 0 | 0 | 0 | For |
| Hartford | 502,646 | 0 | 0 | 0 | For |
| Jackson National | 489,322 | 0 | 0 | 0 | For |
| Goldman Sachs | 462,975 | 0 | 0 | 0 | For |
| TIAA | 453,946 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 372,229 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 368,255 | 0 | 0 | 0 | For |
| Victory Capital | 359,708 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 342,009 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 292,934 | 0 | 0 | 0 | For |
| Voya | 292,649 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 287,303 | 0 | 0 | 0 | For |
| John Hancock | 267,567 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 253,481 | 0 | 0 | 0 | For |
| Lincoln Financial | 180,341 | 0 | 0 | 0 | For |
Showing the 25 largest of 84 asset managers. All 84 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
85% Majority: yes · of votes cast
Description as filed by funds: To elect four Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until his or her successor is elected: Sandra J. Horning, M.D.
REVOLUTION MEDICINES INC.’s own tally for this item (“Elect Director: Sandra J. Horning, M.D.”): 126,395,644 for, 21,497,423 withheld, per its Form 8-K filed June 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 84 asset managers below reported 59,022,889 for, 2,070,239 withheld, 906,788 abstained, 87 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 22,155,786 | 0 | 0 | 0 | For |
| Fidelity | 9,184,298 | 0 | 0 | 0 | For |
| T. Rowe Price | 5,370,441 | 0 | 0 | 0 | For |
| BlackRock | 5,206,044 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 4,687,672 | 0 | 0 | 0 | For |
| JPMorgan | 2,073,815 | 0 | 0 | 0 | For |
| State Street | 1,979,282 | 0 | 0 | 12,741 | For |
| Charles Schwab | 1,964,933 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 956,381 | 0 | 0 | 0 | For |
| Equitable | 441,422 | 0 | 0 | 190,628 | Mixed |
| American Century | 0 | 0 | 0 | 612,358 | Withhold |
| Hartford | 502,646 | 0 | 0 | 0 | For |
| Jackson National | 374,753 | 0 | 114,569 | 0 | Mixed |
| Goldman Sachs | 429,405 | 0 | 0 | 33,570 | Mixed |
| TIAA | 453,946 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 372,229 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 368,255 | 0 | 0 | 0 | For |
| Victory Capital | 1,607 | 0 | 0 | 358,101 | Withhold |
| HARBOR FUNDS | 0 | 0 | 342,009 | 0 | Abstain |
| QUANTITATIVE MASTER SERIES LLC | 292,934 | 0 | 0 | 0 | For |
| Voya | 292,649 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 50,231 | 0 | 237,072 | 0 | Mixed |
| John Hancock | 95,932 | 0 | 171,635 | 0 | Mixed |
| AIG/SunAmerica | 0 | 0 | 0 | 253,481 | Withhold |
| Lincoln Financial | 180,341 | 0 | 0 | 0 | For |
Showing the 25 largest of 84 asset managers. All 84 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
85% Majority: yes · of votes cast
Description as filed by funds: To elect four Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until his or her successor is elected: Sushil Patel, Ph.D.
REVOLUTION MEDICINES INC.’s own tally for this item (“Elect Director: Sushil Patel, Ph.D.”): 126,396,068 for, 21,496,999 withheld, per its Form 8-K filed June 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 84 asset managers below reported 59,022,889 for, 2,070,239 withheld, 906,788 abstained, 87 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 22,155,786 | 0 | 0 | 0 | For |
| Fidelity | 9,184,298 | 0 | 0 | 0 | For |
| T. Rowe Price | 5,370,441 | 0 | 0 | 0 | For |
| BlackRock | 5,206,044 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 4,687,672 | 0 | 0 | 0 | For |
| JPMorgan | 2,073,815 | 0 | 0 | 0 | For |
| State Street | 1,979,282 | 0 | 0 | 12,741 | For |
| Charles Schwab | 1,964,933 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 956,381 | 0 | 0 | 0 | For |
| Equitable | 441,422 | 0 | 0 | 190,628 | Mixed |
| American Century | 0 | 0 | 0 | 612,358 | Withhold |
| Hartford | 502,646 | 0 | 0 | 0 | For |
| Jackson National | 374,753 | 0 | 114,569 | 0 | Mixed |
| Goldman Sachs | 429,405 | 0 | 0 | 33,570 | Mixed |
| TIAA | 453,946 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 372,229 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 368,255 | 0 | 0 | 0 | For |
| Victory Capital | 1,607 | 0 | 0 | 358,101 | Withhold |
| HARBOR FUNDS | 0 | 0 | 342,009 | 0 | Abstain |
| QUANTITATIVE MASTER SERIES LLC | 292,934 | 0 | 0 | 0 | For |
| Voya | 292,649 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 50,231 | 0 | 237,072 | 0 | Mixed |
| John Hancock | 95,932 | 0 | 171,635 | 0 | Mixed |
| AIG/SunAmerica | 0 | 0 | 0 | 253,481 | Withhold |
| Lincoln Financial | 180,341 | 0 | 0 | 0 | For |
Showing the 25 largest of 84 asset managers. All 84 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
81% Majority: yes · of votes cast
Description as filed by funds: To elect four Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until his or her successor is elected: Thilo Schroeder, Ph.D.
REVOLUTION MEDICINES INC.’s own tally for this item (“Elect Director: Thilo Schroeder, Ph.D.”): 119,696,091 for, 28,196,976 withheld, per its Form 8-K filed June 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 84 asset managers below reported 56,828,372 for, 4,264,755 withheld, 906,788 abstained, 87 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 22,155,786 | 0 | 0 | 0 | For |
| Fidelity | 9,184,298 | 0 | 0 | 0 | For |
| T. Rowe Price | 5,370,441 | 0 | 0 | 0 | For |
| BlackRock | 5,206,044 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 4,687,672 | 0 | 0 | 0 | For |
| JPMorgan | 2,073,815 | 0 | 0 | 0 | For |
| State Street | 5,668 | 0 | 0 | 1,986,355 | Withhold |
| Charles Schwab | 1,964,933 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 956,381 | 0 | 0 | 0 | For |
| Equitable | 441,422 | 0 | 0 | 190,628 | Mixed |
| American Century | 0 | 0 | 0 | 612,358 | Withhold |
| Hartford | 502,646 | 0 | 0 | 0 | For |
| Jackson National | 374,753 | 0 | 114,569 | 0 | Mixed |
| Goldman Sachs | 429,405 | 0 | 0 | 33,570 | Mixed |
| TIAA | 453,946 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 372,229 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 368,255 | 0 | 0 | 0 | For |
| Victory Capital | 1,607 | 0 | 0 | 358,101 | Withhold |
| HARBOR FUNDS | 0 | 0 | 342,009 | 0 | Abstain |
| QUANTITATIVE MASTER SERIES LLC | 292,934 | 0 | 0 | 0 | For |
| Voya | 292,649 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 50,231 | 0 | 237,072 | 0 | Mixed |
| John Hancock | 95,932 | 0 | 171,635 | 0 | Mixed |
| AIG/SunAmerica | 0 | 0 | 0 | 253,481 | Withhold |
| Lincoln Financial | 54,529 | 0 | 0 | 125,812 | Mixed |
Showing the 25 largest of 84 asset managers. All 84 are in the interactive database (link above).
Combines 18 wordings of this item as funds reported it.
98% Approved · of votes cast
Prior year: 98.8% for (June 19, 2024 meeting) ▼ 0.5 pts
Description as filed by funds: TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE PROXY STATEMENT PURSUANT TO THE COMPENSATION DISCLOSURE RULES OF THE SECURITIES AND EXCHANGE COMMISSION ("SAY-ON-PAY").
REVOLUTION MEDICINES INC.’s own tally for this item (“3. On a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC”): 145,265,825 for, 2,597,920 against — passed, per its Form 8-K filed June 27, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 22,155,786 | 0 | 0 | 0 | For |
| Fidelity | 9,184,298 | 0 | 0 | 0 | For |
| T. Rowe Price | 5,370,441 | 0 | 0 | 0 | For |
| BlackRock | 5,206,044 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 4,687,672 | 0 | 0 | 0 | For |
| JPMorgan | 2,073,815 | 0 | 0 | 0 | For |
| State Street | 1,991,466 | 557 | 0 | 0 | For |
| Charles Schwab | 1,964,933 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 956,381 | 0 | 0 | 0 | For |
| Equitable | 632,050 | 0 | 0 | 0 | For |
| American Century | 0 | 612,358 | 0 | 0 | Against |
| Hartford | 502,646 | 0 | 0 | 0 | For |
| Jackson National | 489,322 | 0 | 0 | 0 | For |
| Goldman Sachs | 462,975 | 0 | 0 | 0 | For |
| TIAA | 453,946 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 372,229 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 368,255 | 0 | 0 | 0 | For |
| Victory Capital | 359,708 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 342,009 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 292,934 | 0 | 0 | 0 | For |
| Voya | 292,649 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 287,303 | 0 | 0 | 0 | For |
| John Hancock | 267,567 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 253,481 | 0 | 0 | 0 | For |
| Lincoln Financial | 180,341 | 0 | 0 | 0 | For |
Fund voting reports, all 84 managers: 61,143,551 for, 845,612 against, 10,752 abstained, 87 not voted. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT LLC | 12,680,570 | 0 | 0 | 0 | For |
| Wellington | 9,611,508 | 0 | 0 | 0 | For |
| Fidelity | 7,859,812 | 0 | 0 | 0 | For |
| Janus Henderson | 7,773,119 | 0 | 0 | 0 | For |
| T. Rowe Price | 7,601,795 | 0 | 0 | 0 | For |
| BlackRock | 5,798,004 | 30,757 | 0 | 0 | For |
| State Street | 5,269,753 | 557 | 0 | 0 | For |
| BVF INC/IL | 4,982,384 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 4,178,816 | 0 | 0 | 0 | For |
| GV Management Company, L.L.C. | 4,080,700 | 0 | 0 | 0 | For |
| Holocene Advisors, LP | 4,012,457 | 0 | 0 | 0 | For |
| Woodline Partners LP | 3,453,683 | 0 | 0 | 0 | For |
| Paradigm Biocapital Advisors LP | 3,388,995 | 0 | 0 | 0 | For |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 3,384,072 | 0 | 0 | 0 | For |
| JPMorgan | 3,213,632 | 0 | 0 | 0 | For |
| AH Capital Management, L.L.C. | 2,748,523 | 0 | 0 | 0 | For |
| Charles Schwab | 1,989,951 | 0 | 0 | 0 | For |
| Hood River Capital Management LLC | 1,664,162 | 0 | 0 | 0 | For |
| Casdin Capital, LLC | 1,277,463 | 0 | 0 | 0 | For |
| Northern Trust | 1,266,172 | 0 | 0 | 0 | For |
| AMERIPRISE FINANCIAL INC | 1,144,288 | 0 | 0 | 0 | For |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 1,019,407 | 40,210 | 0 | 0 | For |
| Frazier Life Sciences Management, L.P. | 997,455 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 731,858 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 710,667 | 0 | 0 | 0 | For |
Institutional-manager reports, all 224 managers: 110,860,394 for, 1,853,989 against, 15,652 abstained, 2,931 not voted, 226,000 unknown. Showing the 25 largest; every one is in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Prior year: 100.0% for (June 19, 2024 meeting) ▼ 0.1 pts
Description as filed by funds: To ratify the appointment, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025; and
REVOLUTION MEDICINES INC.’s own tally for this item (“2. The appointment, by the audit committee of the Company's board of directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 20”): 157,875,830 for, 214,963 against — passed, per its Form 8-K filed June 27, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment, by the audit committee of the Company's board of directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 84 asset managers below reported 61,988,311 for, 852 against, 10,752 abstained, 87 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 22,155,786 | 0 | 0 | 0 | For |
| Fidelity | 9,184,298 | 0 | 0 | 0 | For |
| T. Rowe Price | 5,370,441 | 0 | 0 | 0 | For |
| BlackRock | 5,206,044 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 4,687,672 | 0 | 0 | 0 | For |
| JPMorgan | 2,073,815 | 0 | 0 | 0 | For |
| State Street | 1,991,908 | 115 | 0 | 0 | For |
| Charles Schwab | 1,964,933 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 956,381 | 0 | 0 | 0 | For |
| Equitable | 632,050 | 0 | 0 | 0 | For |
| American Century | 612,358 | 0 | 0 | 0 | For |
| Hartford | 502,646 | 0 | 0 | 0 | For |
| Jackson National | 489,322 | 0 | 0 | 0 | For |
| Goldman Sachs | 462,975 | 0 | 0 | 0 | For |
| TIAA | 453,946 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 372,229 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 368,255 | 0 | 0 | 0 | For |
| Victory Capital | 359,708 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 342,009 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 292,934 | 0 | 0 | 0 | For |
| Voya | 292,649 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 287,303 | 0 | 0 | 0 | For |
| John Hancock | 267,567 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 253,481 | 0 | 0 | 0 | For |
| Lincoln Financial | 180,341 | 0 | 0 | 0 | For |
Showing the 25 largest of 84 asset managers. All 84 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 186,258,206 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 11.90% |
| 2 | Fidelity | 4.93% |
| 3 | T. Rowe Price | 2.88% |
| 4 | BlackRock | 2.80% |
| 5 | JANUS INVESTMENT FUND | 2.52% |
| 6 | JPMorgan | 1.11% |
| 7 | State Street | 1.07% |
| 8 | Charles Schwab | 1.05% |
| 9 | Manager Directed Portfolios | 0.51% |
| 10 | Equitable | 0.34% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | FARALLON CAPITAL MANAGEMENT LLC | 6.81% |
| 2 | Wellington | 5.16% |
| 3 | Fidelity | 4.22% |
| 4 | Janus Henderson | 4.17% |
| 5 | T. Rowe Price | 4.08% |
| 6 | BlackRock | 3.13% |
| 7 | State Street | 2.83% |
| 8 | BVF INC/IL | 2.67% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 2.24% |
| 10 | GV Management Company, L.L.C. | 2.19% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Vanguard Group | 16,612,035 | 8.92% | Form 13F, quarter ended March 31, 2025 |
| BlackRock | 14,692,392 | 7.89% | Form 13F, quarter ended March 31, 2025 |
| Farallon Partners, L.L.C. | 14,225,683 | 7.64% | Schedule 13G, filed February 9, 2026 |
| Wellington Management | 11,787,921 | 6.33% | Form 13F, quarter ended March 31, 2025 |
| Entities affiliated with Wellington Management Group | 11,401,394 | 6.12% | Proxy statement (DEF 14A), proxy filed April 29, 2025 |
| JANUS HENDERSON GROUP PLC | 9,766,496 | 5.24% | Schedule 13G, filed May 15, 2026 |
| Baker Bros. Advisors LP | 9,455,357 | 5.08% | Schedule 13G, filed February 17, 2026 |
| Thilo Schroeder, Ph.D. | 7,601,087 | 4.08% | Proxy statement (DEF 14A), proxy filed April 29, 2025 |
| FMR (Fidelity) | 7,535,771 | 4.05% | Form 13F, quarter ended March 31, 2025 |
| State Street | 5,804,919 | 3.12% | Form 13F, quarter ended March 31, 2025 |
Percentages above are of 186,258,206 shares outstanding, as reported by REVOLUTION MEDICINES INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At REVOLUTION MEDICINES INC.'s shareholder meeting held June 26, 2025, in the 2024-2025 proxy season, 285 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 2,315 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE… — REVOLUTION MEDICINES INC.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: REVOLUTION MEDICINES INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 27, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from REVOLUTION MEDICINES INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
REVOLUTION MEDICINES INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “REVOLUTION MEDICINES (RVMD) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/revolution-medicines-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.